ad image

zongertinib

1 / 1
Boehringer Ingelheim Pharmaceuticals, Inc.
FDA

Boehringer's Zongertinib ReceivesFDA Priority Review for the Treatment of HER2 (ERBB2)- NSCLC

Boehringer Ingelheim Pharmaceuticals, Inc.

PR-02-25-NI-21Feb 20, 2025
1 / 1